RÉSUMÉ
INTRODUCTION: Trifluridine/tipiracil hydrochloride (FTD/TPI, Lonsurf®) is an oral antineoplastic agent that has been approved as late-stage chemotherapy for colorectal cancer. Its major mechanism of action is the dysfunction of tumoral DNA including DNA strand breaks and decreased replication. Fruquintinib (ELUNATE®) is a novel kinase inhibitor that selectively inhibits the vascular endothelial growth factor receptor-1, -2, and -3. In this study, we evaluated the antitumor activity of combination therapy with FTD/TPI and fruquintinib in vivo. METHODS: The enhancement of the antitumor effects with FTD/TPI and fruquintinib combination, compared to the single drugs given alone was evaluated using two human colorectal cancer xenografts in nude mouse models. FTD/TPI (200 mg/kg) was orally administered for 5 consecutive days followed by 2 days of rest in a 7-day period. Fruquintinib (10 mg/kg) was orally administered consecutively for 2 and 3 weeks in SW48 and HCT 116 tumor-bearing models, respectively. After treatment with these agents, the microvessel density was evaluated by CD31 immunohistochemical analyses. RESULTS: In both models, FTD/TPI and fruquintinib significantly inhibited tumor growth, and the activity of the combined treatment was significantly superior to that of either monotherapy. Body weight loss of greater than 20% was not observed in any group. A histochemical analysis showed nuclei enlargement, abnormal mitosis, and karyorrhexis in the FTD/TPI treatment group. The microvessel density in the HCT 116 tumors treated with FTD/TPI and fruquintinib was significantly lower than that in the control group. CONCLUSION: The combination of FTD/TPI and fruquintinib could be a promising treatment option for colorectal cancer.
Sujet(s)
Antinéoplasiques , Tumeurs colorectales , Démence frontotemporale , Animaux , Souris , Humains , Trifluorothymidine/pharmacologie , Trifluorothymidine/usage thérapeutique , Tumeurs colorectales/traitement médicamenteux , Tumeurs colorectales/anatomopathologie , Démence frontotemporale/traitement médicamenteux , Facteur de croissance endothéliale vasculaire de type A/usage thérapeutique , Antinéoplasiques/pharmacologie , Antinéoplasiques/usage thérapeutique , Association médicamenteuse , Protocoles de polychimiothérapie antinéoplasique/usage thérapeutiqueRÉSUMÉ
PURPOSE: Trifluridine (FTD) is the active component of the nucleoside chemotherapeutic drug trifluridine/tipiracil (FTD/TPI), which is approved worldwide for the treatment of patients with metastatic gastrointestinal cancer. FTD exerts cytotoxic effects via its incorporation into DNA, but FTD has not been detected in the tumor specimens of patients. The purpose of this study was to detect FTD in tumors resected from metastatic colorectal cancer (mCRC) patients who were administered FTD/TPI. Another purpose was to investigate the turnover rate of FTD in tumors and bone marrow in a mouse model. METHODS: Tumors and normal tissue specimens were obtained from mCRC patients who were administered FTD/TPI or placebo at Kyushu University Hospital. Tumors and bone marrow were resected from mice with peritoneal dissemination treated with FTD/TPI. To detect and quantitate FTD incorporated into DNA, immunohistochemical staining of paraffin-embedded specimens (IHC-p staining) and slot-blot analysis of DNA purified from these tissues were performed using an anti-BrdU antibody. IHC-p staining of proliferation and apoptosis markers was also performed. RESULTS: FTD was detected in metastatic tumors obtained from mCRC patients who were administered FTD/TPI, but who had discontinued the treatment several weeks before surgery. In a peritoneal dissemination mouse model, FTD was still detected in tumors 13 days after the cessation of FTD/TPI treatment, but had disappeared from bone marrow within 6 days. CONCLUSION: These results indicate that FTD persists longer in tumors than in bone marrow, which may cause a sustained antitumor effect with tolerable hematotoxicity.
Sujet(s)
Tumeurs colorectales/métabolisme , Tumeurs du foie/métabolisme , Pyrrolidines/analyse , Pyrrolidines/pharmacologie , Thymine/analyse , Thymine/pharmacologie , Trifluorothymidine/analyse , Trifluorothymidine/pharmacologie , Animaux , Apoptose , Prolifération cellulaire , Tumeurs colorectales/traitement médicamenteux , Tumeurs colorectales/anatomopathologie , Association médicamenteuse , Humains , Tumeurs du foie/traitement médicamenteux , Tumeurs du foie/secondaire , Souris , Souris de lignée BALB C , Souris nude , Pronostic , Cellules cancéreuses en culture , Tests d'activité antitumorale sur modèle de xénogreffeRÉSUMÉ
BACKGROUND: Endocrine therapy is clinically administered in hormone-responsive breast cancer. Combinations of fluoropyrimidine S-1 and an aromatase inhibitor or anti-estrogen are considered beneficial in Japan. Herein we assessed new combinations of S-1 and fulvestrant. PATIENTS AND METHODS: Cytotoxicity of fulvestrant and 5-fluorouracil (5-FU) was assessed in hormone-responsive (MCF-7) and non-responsive (MDA-MB-231) breast cancer cell cultures. Fulvestrant and S-1 were evaluated for antitumor activity in mice and their effects on estrogen receptor (ER)-α and progesterone receptor (PgR) levels in MCF-7 xenografts using immunohistochemical methods. RESULTS: Fulvestrant inhibited growth of MCF-7, but not of MDA-MB-231 xenografts. Combinations of 5-FU and fulvestrant were superior to monotherapy in vitro. In vivo antitumor activity of S-1/fulvestrant combination therapy was significantly (p<0.05) enhanced compared to that of both monotherapies. Fulvestrant partially down-regulated expression of ERα and PgR, but in combination with S-1, it almost completely blocked their expression. CONCLUSION: Chemo-endocrine combination therapy using S-1 and fulvestrant is beneficial in estrogen-responsive breast cancer.
Sujet(s)
Antinéoplasiques hormonaux/pharmacologie , Tumeurs du sein/métabolisme , Antagonistes des récepteurs des oestrogènes/pharmacologie , Oestrogènes/métabolisme , Fulvestrant/pharmacologie , Pyrimidines/pharmacologie , Animaux , Lignée cellulaire tumorale , Prolifération cellulaire/effets des médicaments et des substances chimiques , Relation dose-effet des médicaments , Résistance aux médicaments antinéoplasiques/effets des médicaments et des substances chimiques , Synergie des médicaments , Oestrogènes/pharmacologie , Femelle , Humains , SourisRÉSUMÉ
A drug for metastasis prevention is necessary. The orally administered anticancer drug S-1 contributes to cancer therapy. In a mouse xenograft model of metastatic breast cancer from our previous study, the administration of S-1 inhibited lung metastasis. However, the mechanism of inhibition remains elusive. S-1 contains 5-chloro-2,4-dihydroxypyridine (CDHP), which does not have the antigrowth activity, but prevents the degradation of 5-fluorouracil, an anticancer reagent. In this study, we found that CDHP treatment shrinks cell morphology in metastatic basal-like breast cancer cell lines. Wound healing assays showed reduced cell migration in CDHP-treated cells. At the molecular level, CDHP treatment reduced the number of nascent adhesions, whereas the number of mature focal adhesions was not changed. These findings indicate that CDHP impairs focal adhesion formation, which results in a reduction in cell migration. For the in vivo metastasis assay, we used a highly lung-metastatic cell line. We xenografted them into immunodeficient mice, and administered CDHP. To determine whether CDHP prevents metastasis, we measured the weights of harvested lungs. The results showed that the lung weights of the CDHP-treated animals were not significantly different compared to the no-tumor controls, whereas the vehicle group showed a number of metastatic foci and an increase in lung weight. These observations indicate that CDHP administration prevents metastasis. This study reveals a novel effect of CDHP for lung metastasis prevention. Our findings may facilitate the establishment of future metastasis prevention therapies.
Sujet(s)
Tumeurs du sein/prévention et contrôle , Adhérence cellulaire/effets des médicaments et des substances chimiques , Tumeurs du poumon/prévention et contrôle , Tumeurs basocellulaires/prévention et contrôle , Pyridines/pharmacologie , Animaux , Apoptose/effets des médicaments et des substances chimiques , Tumeurs du sein/anatomopathologie , Mouvement cellulaire/effets des médicaments et des substances chimiques , Prolifération cellulaire/effets des médicaments et des substances chimiques , Femelle , Humains , Tumeurs du poumon/secondaire , Souris , Souris de lignée ICR , Souris SCID , Tumeurs basocellulaires/anatomopathologie , Cellules cancéreuses en culture , Tests d'activité antitumorale sur modèle de xénogreffeRÉSUMÉ
We aimed to assess the combined effect of trifluridine (FTD) and ionizing radiation (IR) on colorectal cancer cells in vitro. Colorectal cancer cells, HT-29, HCT-15, and HCT 116, showing low, medium, and high sensitivity to IR, respectively, were treated with the combinations of FTD and IR, and evaluated by the clonogenic survival assay. The radiation dose modification factors (DMFs) were calculated as the ratio of radiation doses producing equivalent surviving fractions following the FTD/IR treatment, or IR alone. DMFs of 4 µM FTD followed by 8 Gy of IR were 2.7, 1.5, and 1.2 for HT-29, HCT-15, and HCT 116, respectively, whereas those of 8 Gy of IR followed by FTD were 1.6, 1.4, and 1.0 for these cells, respectively. Intracellular DNA double-strand break levels after IR and FTD were significantly higher than those observed following the IR treatment alone, regardless of whether the IR was applied before or after FTD. RAD51 expression levels were shown to be increased in FTD and IR treated cells. Apoptotic proteins, such as cleaved PARP and cleaved caspase-3, were detected in cells treated with the combination of FTD and IR, while their expression was not significantly induced after IR or FTD treatment alone. These findings suggest that FTD enhances the efficacy of IR and provide a rationale for designing novel combination chemoradiotherapy regimens containing FTD for patients with rectal cancer that are insensitive to the radiation treatment.
Sujet(s)
Antinéoplasiques/usage thérapeutique , Tumeurs colorectales/traitement médicamenteux , Tumeurs colorectales/radiothérapie , Radiosensibilisants/usage thérapeutique , Trifluorothymidine/usage thérapeutique , Lignée cellulaire tumorale , Chimioradiothérapie , Tumeurs colorectales/métabolisme , Cassures double-brin de l'ADN , Réparation de l'ADN , Relation dose-effet des rayonnements , Cellules HCT116 , Cellules HT29 , Humains , Autoantigène Ku/métabolisme , Rad51 Recombinase/métabolisme , Radiotolérance/effets des médicaments et des substances chimiques , Test clonogénique de cellules souches tumoralesRÉSUMÉ
Drug-tolerant cancer cell subpopulations are responsible for relapse after chemotherapy. By continuously exposing the gastric cancer cell line MKN45 to 5-FU for >100 passages, we established a 5-fluorouracil (5-FU)-tolerant line, MKN45/5FU. Orthotopic xenografts of MKN45/5FU cells in the stomach of nude mice revealed that these cells had a high potential to metastasize to sites such as the liver. Levels of phosphorylated phosphatidylinositide 3-kinase (PI3K) increased both in 5-FU-tolerant subpopulations according to the 5-FU dose, and in gastric submucosal orthotopic xenografts of MKN45/5FU cells. Sequential administration of 5-FU and a PI3K inhibitor, GDC-0941, targeted the downstream ribosomal S6 kinase phosphorylation to significantly suppress 5-FU-tolerant subpopulations and tumor propagation of orthotopic MKN45/5FU xenografts. These results suggest that administration of 5-FU followed by GDC-0941 may suppress disease relapse after 5-FU-based gastric cancer chemotherapy.
Sujet(s)
Antimétabolites antinéoplasiques/pharmacologie , Résistance aux médicaments antinéoplasiques/effets des médicaments et des substances chimiques , Fluorouracil/pharmacologie , Inhibiteurs des phosphoinositide-3 kinases , Animaux , Lignée cellulaire tumorale , Prolifération cellulaire/effets des médicaments et des substances chimiques , Phosphatidylinositol 3-kinases de classe I/antagonistes et inhibiteurs , Phosphatidylinositol 3-kinases de classe I/génétique , Phosphatidylinositol 3-kinases de classe I/métabolisme , Codon , Modèles animaux de maladie humaine , Relation dose-effet des médicaments , Résistance aux médicaments antinéoplasiques/génétique , Variation génétique , Hétérogreffes , Humains , Souris , Tumeurs/génétique , Tumeurs/métabolisme , Tumeurs/anatomopathologie , Phénotype , Phosphatidylinositol 3-kinases/génétique , Phosphatidylinositol 3-kinases/métabolisme , Phosphorylation , Protéome , Protéomique/méthodes , Ribosomal Protein S6 Kinases, 90-kDa/métabolisme , Transduction du signalRÉSUMÉ
To establish the individualized treatment of patients with colorectal cancer, factors associated with chemotherapeutic effects should be identified. However, to the best of our knowledge, few studies are available on this topic, although it is known that the prognosis of patients and sensitivity to chemotherapy depend on the location of the tumor and that the tumor location is important for individualized treatment. In this study, primary tumors obtained from 1,129 patients with colorectal cancer were used to measure the mRNA expression levels of the following genes associated with the effects of standard chemotherapy for colorectal cancer: 5-fluorouracil (5-FU)-related thymidylate synthase (TYMS), dihydropyrimidine dehydrogenase (DPYD) and thymidine phosphorylase (TYMP); folate-related dihydrofolate reductase (DHFR), folylpolyglutamate synthase (FPGS) and gamma-glutamyl hydrolase (GGH); irinotecan-related topoisomerase I (TOP1); oxaliplatin-related excision repair cross-complementing 1 (ERCC1); biologic agent-related vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR). Large-scale population analysis was performed to determine the association of gene expression with the clinicopathological features, in particular, the location of the colorectal cancer. From the results of our analysis of the mRNA expression of these 10 genes, we noted the strongest correlation between DPYD and TYMP, followed by TYMS and DHFR. The location of the colorectal cancer was classified into 4 regions (the right and left-sided colon, rectosigmoid and rectum) and was compared with gene expression. A significant difference in all genes, apart from VEGF, was noted. Of the remaining 9 genes, the highest expression of TYMS and DPYD was observed in the rightsided colon; the highest expression of GGH and EGFR was noted in the left-sided colon; the highest expression of DHFR, FPGS, TOP1 and ERCC1 was noted in the rectosigmoid, whereas TYMP expression was approximately equivalent in the right-sided colon and rectum, and higher than that in other locations. The data generated from this study may prove to be useful for the development of individualized chemotherapeutic treatments for patients with colorectal cancer, and will mean that the tumor location is taken into account.
Sujet(s)
Tumeurs colorectales/génétique , ADN topoisomérases de type I/biosynthèse , Protéines de liaison à l'ADN/biosynthèse , Endonucleases/biosynthèse , Récepteurs ErbB/biosynthèse , Amino-acid ligases/biosynthèse , Dihydrofolate reductase/biosynthèse , Thymidine phosphorylase/biosynthèse , Gamma-glutamyl hydrolase/biosynthèse , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Camptothécine/administration et posologie , Camptothécine/analogues et dérivés , Tumeurs colorectales/traitement médicamenteux , Tumeurs colorectales/anatomopathologie , ADN topoisomérases de type I/génétique , Protéines de liaison à l'ADN/génétique , Endonucleases/génétique , Récepteurs ErbB/génétique , Femelle , Fluorouracil/administration et posologie , Régulation de l'expression des gènes tumoraux/effets des médicaments et des substances chimiques , Humains , Irinotécan , Mâle , Adulte d'âge moyen , Composés organiques du platine/administration et posologie , Oxaliplatine , Amino-acid ligases/génétique , Pronostic , ARN messager/biosynthèse , Dihydrofolate reductase/génétique , Thymidine phosphorylase/génétique , Gamma-glutamyl hydrolase/génétiqueRÉSUMÉ
TAS-102 is a novel oral nucleoside antitumor agent consisting of trifluridine (FTD) and the thymidine phosphorylase inhibitor tipiracil hydrochloride (at a molar ratio of 1:0.5) that was approved in Japan in 2014 for the treatment of unresectable advanced or recurrent colorectal cancer. In the present study, the enhancement of therapeutic efficacy using a combination of TAS-102 and oxaliplatin was evaluated in a xenograft-bearing nude mouse model of colorectal and gastric cancer. TAS-102 was orally administered twice-a-day from day 1 to 14, and oxaliplatin was administered intravenously on days 1 and 8. The in vivo growth-inhibitory activity was evaluated based on the tumor volume and the growth-delay period, was estimated based on the period required to reach a tumor volume five-times greater than the initial volume (RTV5). The tumor growth-inhibitory activity and RTV5 in mice administered TAS-102 with oxaliplatin were significantly superior to those associated with either monotherapy in mice with colorectal (HCT 116, SW-48; p<0.001) and gastric cancer (SC-2, MKN74; p<0.001). MKN74/5FU, a 5-fluorouracil-resistant MKN74 sub-line, was sensitive to both FTD and oxaliplatin in vitro. In vivo, TAS-102 alone was effective in MKN74/5FU, and its anti-tumor activity was significantly enhanced in combination with oxaliplatin (p<0.001). No significant decrease in body weight or toxicity was observed compared to either monotherapy. The present pre-clinical findings indicate that combination of TAS-102 and oxaliplatin is a promising treatment option for colorectal or gastric cancer, and can be utilized in both chemo-naïve tumors and recurrent tumors after 5-fluorouracil treatment.
Sujet(s)
Antinéoplasiques/usage thérapeutique , Protocoles de polychimiothérapie antinéoplasique/usage thérapeutique , Tumeurs colorectales/traitement médicamenteux , Composés organiques du platine/usage thérapeutique , Tumeurs de l'estomac/traitement médicamenteux , Trifluorothymidine/usage thérapeutique , Uracile/analogues et dérivés , Tests d'activité antitumorale sur modèle de xénogreffe , Administration par voie orale , Animaux , Antinéoplasiques/pharmacologie , Protocoles de polychimiothérapie antinéoplasique/pharmacologie , Poids/effets des médicaments et des substances chimiques , Mort cellulaire/effets des médicaments et des substances chimiques , Prolifération cellulaire/effets des médicaments et des substances chimiques , Tumeurs colorectales/anatomopathologie , Association médicamenteuse , Cellules HCT116 , Humains , Souris nude , Composés organiques du platine/pharmacologie , Oxaliplatine , Pyrrolidines , Tumeurs de l'estomac/anatomopathologie , Thymine , Résultat thérapeutique , Trifluorothymidine/administration et posologie , Trifluorothymidine/pharmacologie , Charge tumorale/effets des médicaments et des substances chimiques , Uracile/administration et posologie , Uracile/pharmacologie , Uracile/usage thérapeutiqueRÉSUMÉ
TAS-102 is a novel oral nucleoside antitumor agent consisting of trifluridine and tipiracil hydrochloride at a molar ratio of 1:0.5. TAS-102 was approved in Japan in March 2014 for the treatment of patients with unresectable, advanced or recurrent colorectal cancer that is refractory to standard therapies. In the present study, enhancement of the therapeutic efficacy using a combination therapy of TAS-102 and irinotecan hydrochloride (CPT-11) was evaluated in a colorectal and gastric cancer xenograft-bearing nude mouse model. TAS-102 was orally administered twice a day from day 1 to 14, and CPT-11 was administered intravenously on days 1 and 8. The growth-inhibitory activity was evaluated based on the tumor volume and the growth-delay period, which was estimated based on the period required to reach a tumor volume that was five-times greater than the initial volume (RTV5). The tumor growth-inhibitory activity and the RTV5 of the group receiving TAS-102 with CPT-11 were significantly superior to those of both agents as monotherapy for mice with KM12C, KM12C/5-FU, DLD-1/5-FU, and SC-2 xenografts (p<0.01). No significant decrease in body weight was observed. The present pre-clinical findings indicated that the combination of TAS-102 and CPT-11 is a promising treatment option for colorectal or gastric cancer, not only for chemo-naïve tumors, but also for recurrent tumors after 5-fluorouracil (5-FU)-based chemotherapy.
Sujet(s)
Protocoles de polychimiothérapie antinéoplasique/usage thérapeutique , Tumeurs colorectales/traitement médicamenteux , Tumeurs de l'estomac/traitement médicamenteux , Animaux , Camptothécine/administration et posologie , Camptothécine/analogues et dérivés , Lignée cellulaire tumorale , Association médicamenteuse , Fluorouracil/usage thérapeutique , Humains , Irinotécan , Mâle , Souris , Pyrrolidines , Thymine , Trifluorothymidine/administration et posologie , Uracile/administration et posologie , Uracile/analogues et dérivés , Tests d'activité antitumorale sur modèle de xénogreffeRÉSUMÉ
In this study, combination therapies using the oral fluoropyrimidine tegafur-gimeracil-oteracil (S-1) with several targeted agents or antibodies, were evaluated. First, the effects of tyrosine kinase inhibitors (erlotinib hydrochloride, sorafenib tosilate and sunitinib malate) against human non-small cell lung cancer (NSCLC), breast cancer and colorectal cancer were evaluated in vivo. The effects of the combination of S-1 and targeted antibodies (bevacizumab and cetuximab) against human colorectal cancers was also evaluated in vivo. S-1 and the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, erlotinib, showed a significant inhibition of growth in human NSCLC (Lu-99 and PC-9 cell lines). The antitumor activity of the combination of S-1 and erlotinib against Lu-99 and PC-9 cancer cell lines was significantly superior to either monotherapy (P<0.05). Combination therapy using the multi-tyrosine kinase inhibitors, sorafenib or sunitinib, with S-1 against breast cancer (MX-1 cell line) and NSCLC (NCI-H460 cell line) was significantly superior to either monotherapy (P<0.01). The combination of the anti-vascular endothelial growth factor antibody bevacizumab or the anti-EGFR antibody, cetuximab, with S-1 against human colorectal cancer [Col-1, KM20C (bevacizumab) and DLD-1 (cetuximab) cell lines] and a 5-fluorouracil (5-FU)-resistant cell line (KM12C/5-FU) was significantly superior to either monotherapy (p<0.01). In particular, the growth of the Col-1 cells was completely inhibited by the combination of S-1 and bevacizumab. No toxic mortalities and no significant difference in the body weight changes of the animals treated with S-1 combined with the targeted agents or with the mono-therapies were observed; therefore, the treatments appeared to be well-tolerated. Our preclinical findings indicate that the combination therapies of S-1 and targeted agents are promising treatment options.
RÉSUMÉ
Oxaliplatin is effective when used with 5-fluorouracil (5-FU) and leucovorin, or with capecitabine (COX) for the treatment of colorectal cancer. In this experiment, we investigated the optimal combination schedule and antitumor activity of oral S-1 with oxaliplatin combination therapy (SOX) against human colorectal cancer xenografts in vivo. Using human colon cancer COL-1-bearing nude mice, oxaliplatin was administered at a total dose of 8.3 mg/kg on day 1 alone, on day 8 alone, or in divided doses administered on days 1 and 8 with S-1 (6.9 mg/kg, days 1-14). The antitumor activity of SOX, administered according to the divided schedule was significantly superior to both monotherapies (p<0.01), and the toxicity was tolerable. However, administration on day 8 alone failed to significantly increase the antitumor activity, when compared with that of monotherapy, while administration on day 1 alone was toxic in this model. Next, the efficacy of SOX was compared with that of COX (360 mg/kg, days 1-14). The antitumor effect of SOX was significantly superior to that of COX (p<0.01), with an equivalent toxicity; moreover SOX suppressed COL-1 tumor growth for a longer period of time (2.2 times) than did COX. The antitumor activity of SOX against the 5-FU-resistant colorectal cancer cell line KM12C/5-FU was equivalent to that of COX. The evaluation of intermittent SOX administration in a clinical trial might be of critical value.
Sujet(s)
Protocoles de polychimiothérapie antinéoplasique/pharmacologie , Tumeurs colorectales/traitement médicamenteux , Animaux , Capécitabine , Désoxycytidine/administration et posologie , Désoxycytidine/analogues et dérivés , Calendrier d'administration des médicaments , Association médicamenteuse , Résistance aux médicaments antinéoplasiques , Fluorouracil/administration et posologie , Fluorouracil/analogues et dérivés , Fluorouracil/pharmacologie , Humains , Mâle , Souris , Souris de lignée BALB C , Souris nude , Composés organiques du platine/administration et posologie , Oxaliplatine , Acide oxonique/administration et posologie , Tégafur/administration et posologie , Tests d'activité antitumorale sur modèle de xénogreffeRÉSUMÉ
The present preclinical study was designed to evaluate a new combination therapy comprised of the aromatase inhibitor anastrozole (ANA) and the oral fluoropyrimidines, UFT and S-1 against the estrogen receptor (ER)-positive human breast cancer cell line MCF-7/Arom 14, which was stably transfected with the cDNA of human aromatase. MCF-7/Arom 14 cells showed a high aromatase activity and notably were able to grow in the presence of testosterone and estradiol (E(2)) in vitro. ANA and 5-fluorouracil (5-FU) inhibited cell growth at concentrations of 0.005-10 and 0.2-5 µM, respectively, and the combination of both drugs additively inhibited cell growth. The growth of MCF-7/Arom 14 tumors was significantly inhibited by ANA and S-1 or UFT in vivo. The combination of ANA with S-1 or UFT administered using a 21-day consecutive, metronomic-like regimen significantly enhanced the antitumor efficacy, suppressing tumor growth for 2-4 times longer than monotherapy. To investigate the mechanisms by which S-1 enhances the antitumor activity of ANA, the protein and mRNA expression levels of ER-α in tumor tissue after treatment with S-1, ANA, and the typical chemotherapeutic agents doxorubicin (ADM) or paclitaxel (TXL) were analyzed. The protein and mRNA expression levels of ER-α in the tumor tissue were markedly decreased after treatment with S-1 or S-1 + ANA, but not after treatment with either ADM or TXL. The reduced ER-α level after S-1 treatment might contribute to the increased antitumor activity of ANA by reducing ER-α-induced growth signaling in addition to the decrease in estrogen production induced by ANA. Based on these results, the combination of ANA and S-1 might yield a greater benefit than other chemotherapeutic agents in postmenopausal women with ER-positive breast cancer.
Sujet(s)
Protocoles de polychimiothérapie antinéoplasique/usage thérapeutique , Inhibiteurs de l'aromatase/usage thérapeutique , Tumeurs du sein/traitement médicamenteux , Récepteur alpha des oestrogènes/antagonistes et inhibiteurs , Oestrogènes/pharmacologie , Nitriles/usage thérapeutique , Triazoles/usage thérapeutique , Anastrozole , Animaux , Technique de Western , Tumeurs du sein/métabolisme , Tumeurs du sein/anatomopathologie , Prolifération cellulaire/effets des médicaments et des substances chimiques , Doxorubicine/administration et posologie , Association médicamenteuse , Récepteur alpha des oestrogènes/génétique , Récepteur alpha des oestrogènes/métabolisme , Femelle , Fluorouracil/administration et posologie , Humains , Techniques immunoenzymatiques , Souris , Souris de lignée BALB C , Souris nude , Acide oxonique/administration et posologie , Paclitaxel/administration et posologie , ARN messager/génétique , RT-PCR , Tégafur/administration et posologie , Transplantation hétérologue , Cellules cancéreuses en culture , Uracile/administration et posologieRÉSUMÉ
Triple-negative type breast cancer (TNBC) is a challenge for today's clinical practice. To evaluate the efficacy of anticancer drugs and their combination for the treatment of patients with metastatic TNBC, an appropriate tumor model of metastatic TNBC is required. We developed a breast cancer model in mice that highly metastasizes to lung tissue using an established human TNBC cell line, MDA-MB-231. MDA-MB-231 was implanted intravenously, and lung metastasis nodes were collected. The lung metastasis nodes were then implanted into the mammary fat pad of female SCID mice, followed by surgical extraction. This procedure was repeated an additional two times, and the highly metastatic cell line, MDA-MB-231LLM, was established. After orthotropic implantation and surgical extraction, MDA-MB-231LLM selectively metastasized to the lung, and all of the mice died as a result of lung dysfunction. We then evaluated the anti-metastatic effects and survival period after treatment with S-1, a fluoropyrimidine derivative using this model. Mice were randomized into three groups on day 0. On day 29, lung metastasis was observed in all of the control mice, and the mean lung weight was 2.5 times greater than that of normal mice (P<0.01). However, after 28 days of consecutive treatment with S-1 at a dosage of 10 mg/kg with no apparent toxicity, the lung metastasis nodes were apparently fewer, and the lung weight was significantly (P<0.01) lower than that of the control. In another experiment, the survival period after treatment with S-1 was evaluated. All of the mice in the control group died as a result of lung dysfunction, and the median survival period was 35 days. However, after 28 days of consecutive treatment with S-1 (10 mg/kg), the median survival period was prolonged to 55 days (P<0.01). These results suggest that this new model will be useful for evaluating the anti-metastatic effects of chemotherapeutic agents and the survival period after chemotherapy.
RÉSUMÉ
TAS-102 is an oral anticancer drug composed of trifluorothymidine (TFT) and TPI (an inhibitor of thymidine phosphorylase that strongly inhibits the biodegradation of TFT). Similar to 5-fluorouracil (5FU) and 5-fluoro-2'-deoxyuridine (FdUrd), TFT also inhibits thymidylate synthase (TS), a rate-limiting enzyme of DNA biosynthesis, and is incorporated into DNA. TFT exhibits an anticancer effect on colorectal cancer cells that have acquired 5FU and/or FdUrd resistance as a result of the overexpression of TS. Therefore, we examined the mode of action of TFT-induced DNA damage after its incorporation into DNA. When HeLa cells were treated with TFT, the number of ring-open aldehyde forms at apurinic/apyrimidinic sites increased in a dose-dependent manner, although we previously reported that no detectable excisions of TFT paired to adenine were observed using uracil DNA glycosylases, thymine DNA glycosylase or methyl-CpG binding domain 4 and HeLa whole cell extracts. To investigate the functional mechanism of TFT-induced DNA damage, we measured the phosphorylation of ATR, ATM, BRCA2, chk1 and chk2 in nuclear extracts of HeLa cells after 0, 24, 48 or 72 h of exposure to an IC(50) concentration of TFT, FdUrd or 5FU using Western blot analysis or an enzyme-linked immunosorbent assay (ELISA). Unlike FdUrd and 5FU, TFT resulted in an earlier phosphorylation of ATR and chk1 proteins after only 24 h of exposure, while phosphorylated ATM, BRCA2 and chk2 proteins were detected after more than 48 h of exposure to TFT. These results suggest that TFT causes single-strand breaks followed by double-strand breaks in the DNA of TFT-treated cells. TFT (as TAS-102) showed a more potent antitumor activity than oral 5FU on CO-3 colon cancer xenografts in mice, and such antitumor potency was supported by the increased number of double-strand breaks occurring after single-strand breaks in the DNA of the TFT-treated tumors. These results suggest that TFT causes single-strand breaks after its incorporation into DNA followed by double-strand breaks, resulting in DNA damage. This effect of TFT on DNA may explain its potent anticancer activity in cancer therapy.
RÉSUMÉ
PURPOSE: Our previous study indicated that concurrent administration of 4-OH-tamoxifen (TAM) and 5-fluorouracil (5-FU), but not doxorubicin (Dox), resulted in additive antitumor effects on endocrine-responsive breast cancer cells. We further clarified the effects of combined administration of endocrine therapy with chemotherapeutic agents in this study. METHODS: Concurrent treatment with 4-OH-TAM and paclitaxel (Ptx) was investigated in estrogen receptor (ER)-positive breast cancer cells. Additionally, the combined effects of estrogen depletion from culture medium mimicking estrogen ablative therapy with 5-FU, Dox, and Ptx were investigated. RESULTS: Concurrent treatment with 4-OH-TAM and Ptx yielded less than additive antitumor effects in ER-positive breast cancer cells, as observed with Dox in our previous study. More interestingly, estrogen depletion with 5-FU, but with neither Dox nor Ptx, yielded additive antitumor effects on these cells. We also performed preliminary experiments to elucidate the mechanisms of action responsible for the combined antitumor effects observed. Ptx upregulated the level of expression of one of the molecules related to TAM resistance, Eph-A2, as observed with Dox in our previous study. Estrogen depletion down-regulated the level of expression of one of the molecules related to 5-FU resistance, thymidylate synthase, as observed with 4-OH-TAM in our previous study. CONCLUSIONS: These findings, together with those of our previous study, suggest that concurrent treatment with endocrine therapy, administration of TAM, or estrogen ablative therapy and 5-FU but neither Dox nor Ptx may yield additive antitumor effects on endocrine-responsive breast cancer.
Sujet(s)
Antinéoplasiques/pharmacologie , Tumeurs du sein/anatomopathologie , Doxorubicine/pharmacologie , Antagonistes des oestrogènes/pharmacologie , Fluorouracil/pharmacologie , Tumeurs hormonodépendantes/anatomopathologie , Paclitaxel/pharmacologie , Tamoxifène/analogues et dérivés , Tumeurs du sein/métabolisme , Lignée cellulaire tumorale , Prolifération cellulaire/effets des médicaments et des substances chimiques , Évaluation préclinique de médicament , Interactions médicamenteuses , Oestradiol/pharmacologie , Oestrogènes/pharmacologie , Femelle , Humains , Tumeurs hormonodépendantes/métabolisme , ARN messager/biosynthèse , Récepteur EphA2/biosynthèse , Récepteur EphA2/génétique , Récepteurs des oestrogènes/métabolisme , Tamoxifène/pharmacologie , Thymidylate synthase/biosynthèseRÉSUMÉ
PURPOSE: The sequential addition of tamoxifen (TAM) to chemotherapy seems superior to its concurrent addition in patients with breast cancer. This study was conducted to clarify the hypothesis that there are differential interactions among TAM and chemotherapeutic agents. METHODS: Estrogen receptor (ER)-alpha-positive or -negative breast cancer cells were treated with 4-hydroxy TAM (4OHT), 5-fluorouracil (FU) and/or doxorubicin (Dox). Changes in the expression levels of genes related to sensitivity and resistance to TAM, 5-FU or Dox were tested. RESULTS: Concurrent treatment of 4OHT with 5-FU but not with Dox additively inhibited the growth of ER-alpha-positive cells. 5-FU did not change the expression levels of any tested genes related to either sensitivity or resistance to TAM. Although Dox did not change the expression levels of any genes related to the sensitivity to TAM, Dox significantly increased the expression levels of some genes related to TAM resistance, Eph A-2, ER-beta, Fos and vascular endothelial growth factor. 4OHT significantly decreased thymidilate synthase (TS) activity. CONCLUSIONS: Although the antitumor effect of concurrent 4OHT and 5-FU was additive, that of concurrent 4OHT and Dox was less than additive in ER-alpha-positive cells. The increased expression of genes related to TAM resistance by Dox might be responsible for the interaction. Decreased TS activity by 4OHT might increase the antitumor activity of 5-FU. These findings may provide a preclinical rationale for concurrent use with 5-FU and TAM.
Sujet(s)
Protocoles de polychimiothérapie antinéoplasique/usage thérapeutique , Tumeurs du sein/traitement médicamenteux , Doxorubicine/administration et posologie , Fluorouracil/administration et posologie , Récepteurs des oestrogènes/analyse , Tamoxifène/analogues et dérivés , Tumeurs du sein/composition chimique , Lignée cellulaire tumorale , Résistance aux médicaments antinéoplasiques , Synergie des médicaments , Femelle , Humains , Tamoxifène/administration et posologieRÉSUMÉ
In this study, we demonstrated that chemoimmunotherapy using S-1, a novel oral fluoropyrimidine anticancer drug, combined with lentinan (LNT), a beta (1 --> 3) glucan, was effective in vivo, and we clarified the augmentation of the function of dendritic cells (DCs) in vivo and in vitro. The survival period of Colon-26-bearing mice treated with S-1 + LNT was significantly more prolonged than that of mice treated with S-1 alone (P < 0.05). On the other hand, LNT did not prolong the survival period when combined with S-1 in Colon-26-bearing athymic mice. The frequency of CD86+ DCs infiltrated into Colon-26 was increased in mice treated with S-1 + LNT, and splenic DCs harvested from mice treated with S-1 + LNT showed more potent T-cell proliferation activity than that of DCs from mice treated with S-1 alone (P < 0.05). Furthermore, the activity of cytotoxic T lymphocytes (CTLs) in splenocytes of S-1 + LNT-treated mice was specific and more potent than that of CTLs from mice treated with S-1 alone (P < 0.05). These results suggest that modulation of specific immunity with LNT has a significant role in enhanced antitumor effects through the modification of DC function. We demonstrated that DCs might play an important role in chemotherapy, and the combination therapy of S-1 and LNT presents a promising chemoimmunotherapy, which might lead to better survival for cancer patients.
Sujet(s)
Protocoles de polychimiothérapie antinéoplasique/pharmacologie , Cellules dendritiques/métabolisme , Immunothérapie adoptive , Tumeurs expérimentales/immunologie , Adénocarcinome/immunologie , Adénocarcinome/prévention et contrôle , Adénocarcinome/thérapie , Animaux , Protocoles de polychimiothérapie antinéoplasique/immunologie , Tumeurs colorectales/immunologie , Tumeurs colorectales/prévention et contrôle , Tumeurs colorectales/thérapie , Association thérapeutique , Cellules dendritiques/immunologie , Association médicamenteuse , Fibrosarcome/immunologie , Fibrosarcome/prévention et contrôle , Fibrosarcome/thérapie , Lentinane/administration et posologie , Tumeurs du poumon/immunologie , Tumeurs du poumon/prévention et contrôle , Tumeurs du poumon/thérapie , Lymphomes/immunologie , Lymphomes/prévention et contrôle , Lymphomes/thérapie , Mâle , Souris , Souris de lignée BALB C , Souris de lignée C57BL , Souris nude , Tumeurs expérimentales/prévention et contrôle , Tumeurs expérimentales/thérapie , Acide oxonique/administration et posologie , Pyridines/administration et posologie , Rats , Lignées consanguines de rats , Rate/immunologie , Taux de survie , Lymphocytes T cytotoxiques/métabolisme , Tégafur/administration et posologieRÉSUMÉ
To evaluate the antitumor and antimetastatic efficacy of oral fluoropyrimidines, alone and combined with taxane on human breast cancer xenografts model, we developed a breast cancer model that spontaneously metastasizes to the lung by orthotopic implantation of MDA-MB-435S-HM tumors into the mammary fat pad (mfp) of SCID mice. The activity of the 5-fluorouracil (5-FU)-degrading enzyme dihydropyrimidine dehydrogenase (DPD) was significantly higher in the metastatic tumors than in the primary tumors. Based on this enzymatic characteristic of pulmonary metastases of breast cancer in regard to 5-FU metabolism, we investigated the antitumor activity of two types of oral 5-FU prodrugs, with and without paclitaxel, on both orthotopically implanted breast tumors and metastatic lung tumors in mice. The drugs and doses used were: S-1, a new oral DPD-inhibiting fluoropyrimidine (DIF) 8.3 mg/kg/day, capecitabine 360 mg/kg/day as a non-DIF, and paclitaxel 50 mg/kg, all of which display minimal toxicity in mice. In the primary tumors, paclitaxel and S-1 displayed a significant antitumor activity, with 57 and 41%, respectively inhibition of tumor growth (p < 0.01), but capecitabine had no effect. When S-1 and paclitaxel were combined, they synergistically caused tumor regression (tumor growth inhibition ratio 94%, p < 0.01) in mice compared to capecitabine plus paclitaxel, without any toxicity. In the pulmonary metastasis model, paclitaxel, and both S-1 alone and combined with paclitaxel, but not capecitabine alone or combined with paclitaxel, diaplayed almost complete antimetastatic activity. These results strongly suggest that combination of S-1, as a DIF with taxanes will show a potent high antitumor and antimetastatic effect on refractory human breast cancers, especially those expressing strong DPD activity.
Sujet(s)
Antimétabolites antinéoplasiques/pharmacologie , Antinéoplasiques d'origine végétale/pharmacologie , Tumeurs du sein/traitement médicamenteux , Tumeurs du sein/anatomopathologie , Acide oxonique/pharmacologie , Paclitaxel/pharmacologie , Pyridines/pharmacologie , Tégafur/pharmacologie , Animaux , Tumeurs du sein/médecine vétérinaire , Modèles animaux de maladie humaine , Association médicamenteuse , Femelle , Souris , Souris SCID , Métastase tumorale , Transplantation hétérologueSujet(s)
Antinéoplasiques/pharmacologie , Protocoles de polychimiothérapie antinéoplasique/pharmacologie , Tumeurs du sein/traitement médicamenteux , Oxidoreductases/antagonistes et inhibiteurs , Paclitaxel/administration et posologie , Pyrimidines/pharmacologie , Animaux , Protocoles de polychimiothérapie antinéoplasique/administration et posologie , Protocoles de polychimiothérapie antinéoplasique/usage thérapeutique , Tumeurs du sein/anatomopathologie , Dihydrouracil dehydrogenase (NADP) , Femelle , Floxuridine/administration et posologie , Floxuridine/pharmacologie , Humains , Souris , Souris de lignée ICR , Transplantation tumorale , Tégafur/administration et posologie , Tégafur/pharmacologie , Uracile/administration et posologie , Uracile/pharmacologieRÉSUMÉ
To evaluate the antitumor efficacy against metastatic breast cancer of fluoropyrimidines alone and combined with other chemotherapeutic agents, we developed a murine model of breast cancer metastatic to the lung by orthotopically implanting MDA-MB-435S breast tumors into mice. MDA tumor cells greatly metastasized to lung tissue only after the orthotopically implanted tumors were surgically removed. Measurement of the expression of enzymes involved in 5-FU metabolism showed significantly higher activity of dihydropyrimidine dehydrogenase (DPD) and lower activity of thymidylate synthase (TS) in the MDA metastases than in the orthotopically implanted tumors. Based on the enzymatic properties of metastatic tumors, the minimum toxic doses of UFT (17.5 mg/kg/day) as a DPD-inhibitory fluoropyrimidine (DIF), and of 5'-DFUR (120 mg/kg/day) as a non-DIF, were orally administered to mice with pulmonary metastasis of the breast tumor. The results showed that UFT significantly inhibited the growth of pulmonary metastases of the breast tumors, but 5'-DFUR did not. UFT seemed to inhibit the growth of the pulmonary metastases of the breast tumors in combination with paclitaxel (50 mg/kg) more than in combination with 5'-DFUR, although the antitumor efficacy of neither combination was significantly different from that of paclitaxel alone. These results suggest that combination of DIF with other chemotherapeutic drugs, such as taxanes, is required to attain high antimetastatic and antitumor efficacy against breast tumor metastases, based on the molecular characteristics of the metastatic tumors.